one
new
emerg
mechan
associ
progress
clear
cell
renal
cell
carcinoma
ccrcc
tumor
immun
checkpoint
pathway
consist
cellular
interact
prevent
excess
activ
cell
normal
condit
evas
mechan
mani
tumor
abl
stimul
express
immun
checkpoint
molecul
result
exhaust
phenotyp
cell
restrain
tumor
progress
emerg
clinic
data
highlight
import
one
inhibitori
ligand
receptor
pair
immun
checkpoint
program
deathligand
program
death
prevent
kill
cancer
cell
cytotox
tlymphocyt
receptor
express
activ
cell
b
cell
myeloid
cell
wherea
express
antigenpres
cell
includ
human
peripher
blood
monocyt
stimul
well
activ
b
cell
dendrit
cell
addit
express
constitut
nonlymphoid
tissu
heart
placenta
skelet
muscl
lung
may
serv
downregul
cell
receptor
tcr
signal
cytotox
tlymphocyt
safeguard
autoimmun
mediat
tissu
damag
overexpress
also
found
mani
tumor
type
mediat
immunosuppress
function
interact
protein
includ
immunomodulatori
humanhuman
mab
target
axi
shown
durabl
tumor
control
clinic
trial
good
safeti
profil
fcengin
mab
lack
engag
shown
tumor
regress
rcc
object
respons
rate
stabl
diseas
last
least
week
progressionfre
surviv
week
furthermor
immun
checkpoint
inhibitor
advantag
facilit
memori
respons
unlik
exist
cytotox
target
cancer
therapi
modifi
tcr
call
chimer
antigen
receptor
car
contain
singl
chain
variabl
antibodi
fragment
scfv
previous
select
high
affin
tumorassoci
antigen
power
new
approach
cancer
scfv
present
firstgener
car
link
intracellular
signal
motif
facilit
cell
activ
follow
antigen
bind
secondgener
car
scfv
link
signal
costimulatori
endodomain
thirdgener
car
two
element
link
tandem
costimulatori
endodomain
provid
complet
cell
activ
tcr
recognit
antigenpres
cell
apc
improv
cytokin
product
prolifer
car
cell
promin
exampl
clinic
success
car
cell
therapi
manag
b
cell
malign
secondgener
car
encod
signal
moieti
shown
antitumor
activ
clinic
trial
howev
effect
car
cell
modest
treatment
solid
tumor
due
sever
factor
includ
difficulti
identifi
uniqu
tumor
associ
antigen
ineffici
home
car
cell
tumor
locat
low
persist
infus
function
impair
immunosuppress
microenviron
solid
tumor
effort
counteract
neg
effect
tumor
microenviron
car
cell
function
design
test
selfinactiv
sin
bicistron
lentivir
vector
could
deliv
new
type
doubl
immunotherapi
base
enabl
target
anticarbon
anhydras
caix
car
cell
secret
antibodi
tumor
site
block
cell
exhaust
caix
chosen
target
car
enzym
overexpress
mani
hypox
solid
tumor
wellcharacter
tumorassoci
antigen
overexpress
ccrcc
result
support
feasibl
approach
improv
treatment
ccrcc
potenti
extend
solid
tumor
order
develop
new
car
therapi
caix
rcc
could
block
cell
exhaust
figur
engin
bicistron
lentivir
vector
express
anticaix
scfv
link
signal
domain
car
first
cassett
second
express
cassett
ire
site
figur
control
use
anticaix
car
antib
cell
matur
antigen
bcma
car
construct
secret
irrelev
antisever
acut
respiratori
syndrom
sar
mab
lentivirus
gener
construct
transduc
cell
cultiv
presenc
yield
car
cell
modestli
improv
prolifer
seen
supplementari
figur
maintain
specif
kill
activ
caix
rcc
supplementari
figur
superior
compar
induc
cell
prolifer
previous
describ
percentag
caix
express
rcc
lineag
use
experi
shown
supplementari
figur
car
cell
function
demonstr
supplementari
figur
cell
transduc
car
abl
prolifer
presenc
bead
supplementari
figur
achiev
transduct
level
four
day
supplementari
figur
fourteen
day
transduct
evalu
stabl
longterm
express
car
integr
lentivirus
figur
maintain
around
car
total
igg
level
secret
transduc
cell
also
determin
rang
around
ngml
day
figur
bind
specif
antibodi
human
also
confirm
figur
abil
anticaix
car
cell
undergo
clonal
expans
exclus
presenc
caix
rcc
cell
establish
figur
anticaix
car
cell
expand
significantli
presenc
caix
rcc
cell
figur
anticaix
car
cell
abl
induc
around
decreas
viabil
cell
indic
secret
car
cell
augment
cell
kill
assay
condit
figur
effect
anticaix
car
without
secret
also
analyz
previous
anoth
natur
caix
ccrcc
cell
line
howev
cell
type
studi
herein
due
lack
express
anticaix
car
cell
produc
presenc
cell
demonstr
caix
depend
activ
car
cell
figur
respect
anticaix
car
cell
secret
igg
uniqu
differenti
effect
seen
isoform
abl
induc
around
adcc
rcc
cell
incub
natur
killer
cell
nk
figur
effect
cell
viabil
cytokin
secret
adcc
detect
car
cell
presenc
cell
figur
approxim
decreas
exhaust
marker
found
anticaix
car
group
figur
respect
induct
exhaust
compar
parent
anticaix
point
kill
activ
anticaix
car
cell
retest
cell
shown
figur
anticaix
car
cell
without
lost
kill
activ
rcc
vitro
level
similar
irrelev
car
group
establish
anticaix
car
cell
becom
exhaust
contrast
rcc
viabil
reduc
anticaix
car
group
car
group
respect
data
provid
evid
checkpoint
blockad
elicit
secret
igg
lead
diminish
cell
exhaust
nsg
mice
use
establish
orthotop
rcc
model
inject
rcc
cell
kidney
capsul
follow
iv
inject
car
untransduc
cell
day
repeat
treatment
day
lower
dose
cell
treat
mice
system
maintain
prolifer
car
cell
avoid
bia
molecul
could
exert
tumor
growth
data
figur
demonstr
three
anticaix
car
cell
group
show
decreas
rcc
growth
compar
irrelev
antibcma
car
cell
untransduc
cell
cours
experi
mark
antitumor
effect
exhibit
anticaix
car
cell
secret
becom
evid
day
figur
howev
even
one
week
iv
treatment
car
cell
observ
tumor
time
smaller
car
cell
compar
parent
anticaix
car
cell
two
control
group
supplementari
figur
also
analyz
cell
surviv
mous
blood
gaug
surviv
passiv
transfer
model
day
observ
proport
human
cell
within
pbmc
supplementari
figur
one
week
second
inject
day
group
tumor
time
smaller
control
group
time
smaller
anticaix
car
cell
without
secret
figur
supplementari
figur
day
group
mice
treat
car
cell
secret
antibodi
tumor
time
smaller
control
group
figur
supplementari
figur
excis
tumor
weight
also
lower
mice
treat
car
cell
secret
antibodi
particularli
evid
antibodi
group
figur
analysi
excis
tumor
show
around
tumorinfiltr
lymphocyt
til
group
supplementari
figur
one
import
effect
observ
anticaix
car
cell
secret
antibodi
vivo
abil
reduc
express
exhaust
marker
shown
figur
car
cell
observ
decreas
approxim
express
respect
compar
parent
anticaix
car
cell
treat
group
data
provid
evid
local
secret
antibodi
decreas
express
surfac
marker
associ
cell
exhaust
effector
activ
car
ttil
cell
influenc
rcc
prolifer
vivo
also
evalu
immunohistochem
stain
excis
tumor
tissu
granzym
b
stain
show
highest
percentag
posit
cell
rcc
tumor
treat
anticaix
car
cell
secret
follow
cell
higher
parent
anticaix
car
cell
control
group
figur
addit
express
decreas
dramat
tumor
treat
anticaix
car
cell
secret
either
igg
isotyp
compar
parent
anticaix
car
cell
figur
mab
use
ihc
recogn
differ
domain
mab
secret
lentiviru
decreas
express
observ
group
treat
car
cell
probabl
due
endocytosi
tumor
cell
death
moreov
greater
decreas
express
observ
iggsecret
group
compar
parent
anticaix
car
cell
seen
ihc
imag
figur
total
dab
pixel
count
graph
figur
intens
express
compar
among
posit
stain
nuclei
figur
car
cell
group
show
shift
toward
greater
number
low
posit
cell
suggest
isoform
potent
vivo
green
bar
studi
demonstr
car
cell
effect
ccrcc
kill
vivo
least
part
explain
decreas
exhaust
document
secret
antibodi
activ
bind
tumor
cell
inject
mice
freshli
isol
nk
cell
day
euthanasia
stain
nk
cell
accumul
tumor
shown
figur
stain
singl
cell
suspens
til
show
mark
statist
signific
presenc
nk
cell
tumor
mice
treat
car
cell
compar
group
includ
anticaix
car
cell
secret
cell
bind
human
nk
cell
increas
nk
cell
group
til
also
detect
quantifi
ihc
figur
data
provid
strong
evid
secret
antibodi
maintain
local
target
recognit
abl
recruit
nk
effect
cell
tumor
site
studi
focus
effort
develop
singl
target
car
cell
immunotherapi
capac
chang
tumor
microenviron
known
contribut
immun
escap
solid
tumor
built
immunotherapi
platform
base
scientif
principl
show
clinic
success
import
sinc
car
cell
immun
dysregul
reach
cancer
site
due
tumor
cell
contact
complex
solubl
mediat
milieu
impact
function
inde
chang
microenviron
basi
encourag
clinic
respons
mab
therapi
aim
restor
cell
antitumor
immun
engin
car
cell
secret
deliv
high
concentr
human
mab
molecul
involv
immun
checkpoint
blockad
tumor
site
could
diminish
potenti
becom
exhaust
well
lead
tran
revers
exhaust
immun
cell
accumul
tumor
site
accomplish
use
selfinactiv
bicistron
lentivector
engin
produc
human
mabsecret
car
cell
use
mous
model
ccrcc
demonstr
proofofprincipl
anticaix
car
cell
arm
deliv
immunomodulatori
mab
tumor
site
superior
parent
anticaix
car
cell
abil
resist
exhaust
vitro
vivo
result
signific
improv
antitumor
activ
seen
vivo
abil
secret
mab
recruit
immun
cell
tumor
also
demonstr
upregul
ccrcc
cell
well
document
believ
involv
induc
cell
exhaust
engag
tumor
recruit
cell
treatment
ccrcc
checkpoint
blockad
inhibitor
shown
promis
clinic
result
anticaix
car
cell
stabli
express
secret
mab
studi
compar
parent
anticaix
car
cell
cell
control
mabsecret
car
cell
maintain
capac
undergo
clonal
expans
contact
caix
rcc
cell
secret
high
level
remark
vitro
result
show
secret
interact
rcc
cell
revers
upregul
exhaust
marker
restor
tumor
cell
kill
moreov
anticaix
car
cell
secret
isotyp
also
abl
induc
adcc
vitro
orthotop
model
human
ccrcc
nsg
mice
car
cell
abl
revert
cell
exhaust
evidenc
downregul
exhaust
marker
til
anticaix
car
cell
show
markedli
enhanc
antitumor
effect
decreas
tumor
growth
weight
compar
parent
anticaix
car
cell
addit
secret
abl
bind
target
complex
tumor
milieu
induc
downregul
moreov
upregul
granzym
b
express
anticaix
car
cell
secret
provid
strong
evid
restor
kill
activ
car
cell
tumor
site
decreas
stain
show
reduct
prolifer
tumor
cell
mechan
enhanc
tumor
cell
kill
unknown
nsg
myeloid
cell
bind
human
may
role
tumor
cell
clearanc
presenc
isotyp
known
express
activ
cell
togeth
potent
kill
target
cell
murin
pmn
may
contribut
superior
anticaix
car
cell
vivo
anoth
import
proofofprincipl
experi
involv
inject
human
nk
cell
blood
mice
one
day
euthanasia
previou
experi
orthotop
ccrcc
model
nsg
mice
show
human
nk
cell
last
day
mous
blood
reason
inject
nk
cell
perform
end
experi
result
demonstr
specif
recruit
human
nk
cell
tumor
mice
treat
anticaix
car
cell
result
also
demonstr
local
secret
retain
tumor
site
rapidli
diffus
blood
circul
result
reflect
potenti
increas
therapeut
efficaci
car
cell
appli
human
sinc
bind
induc
nkmediat
adcc
local
accumul
nk
cell
also
facilit
develop
antitumor
cytotox
lymphocyt
respons
increas
number
tumorspecif
cell
grow
censu
field
cancer
immunotherapi
combin
therapi
requir
achiev
cancer
cure
inde
combin
mab
therapi
shown
enhanc
efficaci
clinic
trial
appear
exert
effect
distinct
popul
cell
addit
mous
model
breast
cancer
group
mice
treat
car
cell
repeat
inject
mab
tumor
implant
show
greater
car
cell
function
less
cell
exhaust
enhanc
tumor
cell
kill
result
demonstr
arm
secondgener
anticaix
car
cell
constitut
secret
igg
retain
rcc
milieu
also
show
reduc
cell
exhaust
enhanc
antitumor
activ
possibl
singl
combin
anticanc
agent
deliv
persist
high
local
concentr
mab
may
provid
signific
treatment
advantag
solid
tumor
local
express
mab
may
also
result
reduc
system
toxic
firstgener
car
cell
express
murin
anticaix
scfv
previous
develop
test
vivo
treatment
metastat
ccrcc
protocol
util
multipl
car
cell
inject
associ
treatment
result
toxic
compris
limit
liver
enzym
elev
caus
recognit
caix
express
low
level
bile
duct
epithelium
potenti
mechan
toxic
reveal
gener
gener
human
antibodi
well
cellmedi
immun
murin
scfv
may
contribut
toxic
promot
car
cell
neutral
clearanc
later
studi
also
perform
pretreat
patient
low
dose
human
anticaix
mab
use
attenu
activ
car
cell
bile
duct
epitheli
cell
result
suggest
use
human
anticaix
scfv
newer
gener
car
vector
could
greatli
improv
effici
caixtarget
car
cell
conclus
anticaix
car
cell
secret
diminish
cell
exhaust
improv
car
cell
treatment
ccrcc
vivo
propos
modif
car
structur
design
replac
costimulatori
domain
may
enhanc
car
cell
persist
vivo
improv
effici
treatment
addit
forese
combin
mab
direct
molecul
involv
immun
escap
either
express
tandem
bispecif
mab
among
next
step
explor
achiev
even
higher
level
antitumor
immun
human
ccrcc
cell
line
obtain
dr
gerd
ritter
memori
sloankett
ny
cell
cultiv
rpmi
medium
life
technolog
supplement
vv
heatinactiv
fetal
bovin
serum
fb
gibco
iuml
penicillin
streptomycin
cell
maintain
complet
rpmi
medium
contain
mm
hepe
iuml
peprotech
ad
medium
everi
day
atcc
lentix
clontech
cell
grown
dmem
medium
life
technolog
supplement
fb
iuml
penicillin
streptomycin
tumor
cell
line
transduc
luciferas
lentivir
transduct
maintain
cell
select
cell
popul
fluoresc
activ
cell
sort
cell
engin
express
high
level
human
caix
select
sort
human
antibodi
ab
clone
previous
select
use
billionmemb
human
singlechain
variabl
fragment
scfv
antibodi
phage
display
librari
fulllength
paramagnet
proteoliposom
clone
mab
select
studi
due
abil
effici
block
bind
data
shown
dna
sequenc
encod
scfv
codon
optim
mammalian
express
synthes
genewiz
ndei
clai
restrict
site
clone
place
zsgreen
humanfc
stabil
lentivir
vector
anticaix
neg
control
scfv
replac
antisever
acut
respiratori
syndrom
sar
scfv
clone
lentivir
vector
anticaix
scfv
car
construct
contain
antisar
also
replac
antib
cell
matur
antigen
bcma
procedur
result
four
construct
lentiviru
product
anticaix
car
abl
express
anticaix
car
abl
express
anticaix
car
abl
express
irrelev
antisar
mab
anticaixantisar
refer
parent
anticaix
car
antibcma
car
abl
express
irrelev
antisar
mab
antibcmaantisar
lentivirus
produc
transient
transfect
five
plasmid
cell
use
polyethyleneimin
pei
briefli
confluent
cell
cm
plate
nalg
nunc
transfect
total
five
plasmid
structur
plasmid
hiv
gagpol
pmdtat
prccmvrev
env
vsvg
car
encod
plasmid
anticaixantisar
antibcmaantisar
viru
supernat
concentr
use
lentix
concentr
clontech
follow
manufactur
instruct
kept
frozen
blood
collar
collect
healthi
volunt
obtain
blood
bank
brigham
woman
hospit
boston
dfci
approv
human
protocol
human
peripher
blood
mononuclear
cell
pbmc
separ
use
ficollpaqu
plu
ge
healthcar
nj
dynabead
posit
isol
life
technolog
use
isol
cell
pbmc
activ
dynabead
human
tactiv
life
technolog
use
ratio
subsequ
cell
transduc
lentivirus
multipl
infect
diethylaminoethyl
assay
perform
triplic
use
cell
three
differ
healthi
donor
abil
cell
transduc
variabl
among
differ
donor
case
number
cell
ad
experi
correct
transduct
avoid
bia
transduct
cell
confirm
analysi
cell
stain
human
caixhuman
fc
produc
lab
human
bcmamousefc
ab
bioscienc
develop
apcconjug
mous
antihuman
igg
ab
southern
biotech
goatantimous
igg
ab
biolegend
respect
count
bead
molecular
probe
use
prolifer
clonal
expans
assay
sampl
analyz
lsr
fortessa
facscalibur
bd
bioscienc
data
analyz
use
flowjo
softwar
analyz
statu
cell
exhaust
car
cell
cultur
presenc
uml
peprotech
dynabead
human
activ
day
period
car
cell
cocultur
cell
day
order
stimul
exhaust
car
cell
assay
til
collect
vivo
assay
stain
fitcconjug
antihuman
peconjug
antihuman
antihuman
antibodi
biolegend
pacif
blueconjug
antihuman
analyz
flow
cytometri
verifi
express
level
caix
differ
rcc
cell
lineag
use
antihuman
caix
mab
clone
biotinyl
mous
antihuman
biolegend
primari
antibodi
detect
use
apcconjug
antihuman
ab
southern
biotech
peconjug
avidin
biolegend
respect
analyz
fac
car
transduc
cell
preactiv
bead
maintain
two
day
well
plate
contain
ml
complet
rpmi
medium
life
technolog
uml
hour
medium
remov
dose
total
igg
igg
total
level
igg
secret
medium
transduc
cell
detect
use
human
igg
elisa
quantit
set
bethyl
laboratori
ab
secret
transduc
car
cell
purifi
protein
sepharos
bead
ge
healthcar
biotinyl
use
ezlink
sulfonhslcbiotin
thermo
scientif
antibodi
incub
recombin
humanfc
protein
preimmobil
maxisorp
plate
nunc
hour
rt
biotinyl
antibodi
detect
incub
streptavidinhrp
h
develop
tmb
peroxidas
substrat
tmb
stop
solut
kpl
absorb
read
nm
cell
irradi
rad
seed
per
well
car
cell
ad
cultur
medium
contain
iuml
human
everi
two
day
cell
split
maintain
suitabl
densiti
restimul
tumor
cell
weekli
cell
number
count
week
week
fac
plate
well
plate
overnight
four
day
car
cell
transduct
ad
rcc
cell
ratio
effector
cell
tumor
cell
e
incub
car
cell
remov
viabil
tumor
cell
assay
mtt
assay
life
technolog
adcc
assay
rcc
cell
incub
h
car
cell
supernat
adjust
respect
ab
cell
incub
nk
cell
tumor
cell
h
lactat
dehydrogenas
ldh
measur
supernat
cytotox
nonradioact
cytotox
assay
promega
analysi
cytokin
secret
rcc
cell
seed
well
plate
follow
car
cell
tumor
cell
addit
incub
supernat
remov
analyz
secret
use
human
human
elisa
readysetgo
kit
ebiosci
cell
suspend
cultur
medium
dilut
life
technolog
inject
left
subren
capsul
weekold
male
nsg
mice
jackson
laboratori
week
tumor
implant
confirm
bioluminesc
bli
imag
use
xenogen
ivi
imag
system
life
technolog
car
cell
untransduc
cell
inject
intraven
tail
vein
day
n
mice
per
group
blood
donor
use
gener
car
cell
group
mice
group
inject
car
cell
differ
donor
tumor
bli
quantifi
day
car
cell
inject
second
inject
car
untransduc
cell
made
day
mice
control
group
present
sign
distress
day
post
tumor
engraft
sacrif
standard
inhal
tumor
harvest
weigh
kidney
tumor
mice
divid
two
equal
part
one
fragment
small
piec
digest
collagenas
uml
dnase
mgml
til
extract
analyz
express
exhaust
marker
percentag
car
cell
flow
cytometri
part
fix
buffer
formaldehyd
immunohistochemistri
ihc
two
mice
group
inject
nk
cell
day
euthanasia
nk
cell
present
tumor
stain
ab
analyz
fac
fourmicromet
section
formalinfix
paraffinembed
tissu
prepar
convent
ihc
stain
minut
rabbit
antihuman
granzym
b
polyclon
ab
abcam
mous
antihuman
mab
clone
boston
rabbit
antihuman
polyclon
ab
vector
follow
secondari
hrp
conjug
antirabbit
antimous
ab
mab
use
ihc
recogn
differ
domain
mab
secret
lentiviru
slide
develop
use
dab
counterstain
hematoxylin
quantif
ihc
imag
perform
use
ihc
profil
plugin
imagej
softwar
statist
signific
data
evalu
use
anova
tukey
post
test
use
ibm
spss
statist
softwar
version
p
consid
signific
